Recordati Faces $11.5B Takeover by CVC and GBL

A significant shift is underway in the European pharmaceutical sector as CVC Capital Partners Fund IX and Groupe Bruxelles Lambert (GBL) launch a substantial takeover bid for the Italian-listed firm Recordati. The voluntary total tender offer, valued at approximately €10.7 billion (roughly $11.5 billion USD), commenced on August 31st and will remain open until October 15th. This move signals a major private equity play within the healthcare industry, targeting a company with a long-standing presence and a diverse portfolio of treatments.

The financing structure underpinning this ambitious acquisition is as noteworthy as the deal itself. The consortium has secured a robust financial package, including up to €4.525 billion in equity contributed by the sponsors and their co-investors. Complementing this equity injection is a substantial debt facility, comprising over €4.1 billion in bridge financing drawn from comprehensive banking lines totaling up to €6.05 billion. This significant credit commitment has been arranged with a syndicate of approximately twenty major international banks, underscoring the scale and confidence in the transaction.

Adding another layer to the financing is the issuance of up to €1.53 billion in senior PIK toggle notes. These notes have attracted interest from prominent players in the private credit market and institutional investors. Key participants in this debt tranche include heavyweight firms such as Goldman Sachs Asset Management, KKR, Blackstone, Clearlake Capital Group, CVC Capital Solutions, and Marathon Asset Management. Additionally, a club deal involving clients of Banor SIM is also participating, highlighting a diversified approach to funding this large-scale buyout.

The offer price stands at €51.29 per share, with payments scheduled to commence on October 23rd. Should the conditions be met, the offer period may be extended from October 26th to 30th, with a subsequent payment on November 9th. The ultimate goal of this tender offer is the delisting of Recordati from the stock exchange, marking a transition from public to private ownership. This development follows closely on the heels of regulatory approvals, including clearance from the EU Antitrust authorities in early August and the Italian market regulator Consob's approval of the offer document in July.

This transaction represents a significant transition for CVC Capital Partners, with the new Fund IX taking the lead. The current controlling shareholder, Rossini sarl, which holds 46.82% of Recordati and has irrevocably committed to the offer, was originally formed in 2018. That entity was established by a consortium including CVC Capital Partners Fund VII, PSP Investments, StepStone, and AlpInvest to acquire control of Recordati from the founding Recordati family via their holding company Fimei. The initial transaction valued Recordati at an enterprise value of €6.5 billion.

The pharmaceutical industry in Europe continues to be a focal point for private equity, driven by factors such as innovation in drug development, an aging population increasing demand for healthcare, and the potential for operational efficiencies through consolidation. Recordati, with its established market position and focus on specialty and rare diseases, presents an attractive target for sponsors looking to leverage their expertise for growth and value creation. The substantial debt financing indicates a belief in the company's stable cash flows and future earnings potential, crucial elements for servicing such a large debt load.